Skip to main content

Advertisement

Table 1 Baseline characteristics and pulmonary function parameters by study group

From: Is the purinergic pathway involved in the pathology of COPD? Decreased lung CD39 expression at initial stages of COPD

Characteristic COPD (N = 17) NOS (N = 16) NS (N = 13) p-value
Male gender, n (%) 15 (88) 16 (100) 5 (38) < 0.001
Age, years 64.4 ± 7 61.0 ± 11 61 ± 14 0.617
BMI, kg/m2 25.4 ± 4.2 27.4 ± 4.5 27.2 ± 4.2 0.364
Current smokers, n (%) 3 (17) 9 (56) < 0.001
Pack-years 51.47 ± 15.52 39.87 ± 19.09 0.072
Diabetes Mellitus, n (%) 1 (6) 6 (37.5) 0.005
Fast basal glucose, mmol/L 5.2 [4.7–6.6] 6.5 [5.2–7.3] 5.3 [4.9–6.3] 0.056
Systemic hypertension, n (%) 8 (34.8) 7 (43.7) 5 (31.3) 0.896
Inhaled CS, n (%) 5 (29.0) 0 (0) 1 (7) 0.039
FVC, L 3.3 ± 0.7 4 ± 0.9 3.5 ± 1 0.079
FVC, % predicted 89 ± 14 101 ± 17 111 ± 23 0.008
FEV1, L 1.9 ± 0.5 3 ± 0.6 2.7 ± 0.8 < 0.001
FEV1, % predicted 64 ± 16 97 ± 14 106 ± 23 < 0.001
% FEV1/FVC 57 ± 10 76 ± 5 77 ± 5 < 0.001
DLCO,% predicted 69 ± 14 89 ± 17 93 ± 18 < 0.001
Leukocytes count, x10E9/L 8.7 ± 1.9 8.2 ± 2 6.9 ± 1.5 0.038
C-reactive protein, mg/L 5.4 [2.1–10.6] 2.1 [1.0–10.9] 1.8 [1–2.7] 0.028
  1. Data are presented as mean ± SD or median [25th–75th percentile]
  2. COPDChronic Obstructive Pulmonary Disease, NOS Non-obstructed smokers, NS Never smokers, BMI Body mass index, CS Corticosteroids, FVC Forced vital capacity, FEV 1 Forced expiratory volume in one second, DL CO Diffusing lung capacity for carbon monoxide. A p-value < 0.05 was considered statistically significant